摘要
目的探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血浆中D-二聚体水平与患者化疗预后的相关性。方法本研究回顾性分析了2008年1月至2010年12月我院行GP方案化疗的晚期NSCLC患者135例,分析其化疗前血浆D-二聚体含量与临床病理特征及无进展生存时间(progression-free survival,PFS)和总生存时间(overall survival,OS)的关系。结果Ⅳ期的NSCLC患者血浆D-二聚体表达水平相对更高,差异有统计学意义(P<0.05);晚期NSCLC伴血浆D-二聚体表达阳性患者的PFS(5.3个月/10.6个月,P<0.05)和OS(11.8个月/20.4个月,P<0.05)均明显缩短;多因素回归分析化疗前血浆D-二聚体表达水平是影响晚期NSCLC患者预后的独立因素(P<0.05)。结论 D-二聚体可作为晚期NSCLC患者预后判断的实验室辅助诊断指标。
Objective To examine the association of pre-chemotherapy patients＇plasma D-dimer levels and the prognosis of advanced NSCLC patients. Methods Plasma D-dimer levels of 135 advanced of NSCLC patients were measured and correlated with clinical features, progression-free survival （PFS） and overall survival （OS）. Results A significant correlation was identified between plasma D-dimer levels and clinical stage（P 〈 0.05）. Patients with positivity of D-dimer had significantly shorter PFS and OS than those with negativity （P 〈 0.05）. Multivariate analysis revealed that pre-chemotherapy D-dimer levels were a significant independent factor for DFS and OS in advanced NSCLC patients （P〈0.05）. Conclusion D-dimer levels provide prognostic information in addition to that of imaging studies.
出处
《分子诊断与治疗杂志》
2014年第6期384-387,共4页
Journal of Molecular Diagnostics and Therapy
基金
国家自然科学基金(81172081)
中国博士后基金(2012M521189)
浙江省博士后择优专项基金(Bsh1202064)
浙江省自然科学基金(LY13H160024)
